Global Health Investment Corporation
GHIC is a nonprofit venture investor that mobilizes private, philanthropic and public capital to accelerate development, commercialization, and access to vaccines, therapeutics, diagnostics, medical devices and other health technologies that address global public health needs, health equity, and health security. GHIC operates an impact investment fund (GHIF), manages a public–private venture partnership with BARDA to finance health security technologies, and runs grant and catalytic investment initiatives to seed early-stage research and funds.
Industries
Nr. of Employees
small (1-50)
Portfolio
GHIF portfolio company; developed Jada system for postpartum hemorrhage. Acquired by Organon (announcement June 16, 2021).
#Medical devices / maternal health
GHIC participated in Biolinq's $100M Series B round; initial global health security portfolio investment under the BARDA partnership. Senior Advisor to GHIC joined Biolinq board (Zina Affas Besse).
#Wearable biosensors / diagnostics
GHIC participated in a financing to support Endpoint Health's precision therapeutics platform and to advance its Antithrombin III program toward Phase II for sepsis.
#Therapeutics / precision immunology
GHIC participated in the first close of a €44M Series D to support biologics manufacturing capabilities and global expansion.
#Biologics manufacturing / biomanufacturing
GHIC invested $2M as a strategic investor in Vaxess's Series B; Vaxess developing MIMIX sustained-release vaccine patch and advancing a Phase 1 influenza vaccine patch trial.
#Vaccine delivery / patches
GHIC participated in a $25M seed round to advance Monod's de novo protein-based biosensor LucCage platform for rapid point-of-care diagnostics.
#Diagnostics / biosensors
GHIF portfolio company; developed Jada system for postpartum hemorrhage. Acquired by Organon (announcement June 16, 2021).
#Medical devices / maternal health
GHIC participated in Biolinq's $100M Series B round; initial global health security portfolio investment under the BARDA partnership. Senior Advisor to GHIC joined Biolinq board (Zina Affas Besse).
#Wearable biosensors / diagnostics
GHIC participated in a financing to support Endpoint Health's precision therapeutics platform and to advance its Antithrombin III program toward Phase II for sepsis.
#Therapeutics / precision immunology
GHIC participated in the first close of a €44M Series D to support biologics manufacturing capabilities and global expansion.
#Biologics manufacturing / biomanufacturing
GHIC invested $2M as a strategic investor in Vaxess's Series B; Vaxess developing MIMIX sustained-release vaccine patch and advancing a Phase 1 influenza vaccine patch trial.
#Vaccine delivery / patches
GHIC participated in a $25M seed round to advance Monod's de novo protein-based biosensor LucCage platform for rapid point-of-care diagnostics.
#Diagnostics / biosensors